In vitro dissolution of proton-pump inhibitor products intended for paediatric and geriatric use in physiological bicarbonate buffer.
Proton-pump inhibitor (PPI) products based on enteric coated multiparticulates are design to meet the needs of patients who cannot swallow tablets such as children and older adults. Enteric coated PPI preparations exhibit delays in in vivo absorption and onset of antisecretory effects, which is not reflected by the rapid in vitro dissolution in compendial pH 6.8 phosphate buffer commonly used for assessment of these products. A more representative and physiological medium, pH 6.8 mHanks bicarbonate buffer, was used in this study to evaluate the in vitro dissolution of enteric coated multiparticulate-based PPI products. Commercially available omeprazole, lansoprazole and esomeprazole products were subject to dissolution tests using USP-II apparatus in pH 4.5 phosphate buffer saline for 45 min (acid stage) followed by pH 6.8 phosphate buffer or pH 6.8 mHanks bicarbonate buffer. In pH 6.8 phosphate buffer, all nine tested products displayed rapid and comparable dissolution profiles meeting the pharmacopeia requirements for delayed release preparations. In pH 6.8 mHanks buffer, drug release was delayed and failed the pharmacopeia requirements from most enteric coated preparations. Despite that the same enteric polymer, methacrylic acid-ethyl acrylate copolymer (1:1), was applied to all commercial multiparticulate-based products, marked differences were observed between dissolution profiles of these preparations. The use of pH 6.8 physiological bicarbonate (mHanks) buffer can serve as a useful tool to provide realistic and discriminative in vitro release assessment of enteric coated PPI preparations and to assist rational formulation development of these products.
Department of Pharmacy, School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK. Electronic address: f.liu3@herts.ac.uk.
Fang
F
Liu
Department of Pharmacy, School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK.
Honaz
H
Shokrollahi
D000367:Age Factors; D001639:Bicarbonates / Q000737:chemistry; D002021:Buffers; D002626:Chemistry, Pharmaceutical; D064098:Esomeprazole / Q000737:chemistry; D005853:Geriatrics; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007700:Kinetics; D064747:Lansoprazole / Q000737:chemistry; D009853:Omeprazole / Q000737:chemistry; D010316:Particle Size; D010372:Pediatrics; D010710:Phosphates / Q000737:chemistry; D054328:Proton Pump Inhibitors / Q000737:chemistry*; D012965:Sodium Chloride / Q000737:chemistry; D012995:Solubility; D013608:Tablets, Enteric-Coated; D013678:Technology, Pharmaceutical / Q000379:methods
D001639:Bicarbonates; D002021:Buffers; D010710:Phosphates; D054328:Proton Pump Inhibitors; D013608:Tablets, Enteric-Coated; D064747:Lansoprazole; D012965:Sodium Chloride; D009853:Omeprazole; D064098:Esomeprazole
Bicarbonate media; Biorelevant dissolution; Dysphagia; Modified release; Pellets; Physiological buffers